Sutro Biopharma (STRO) Income towards Parent Company (2017 - 2026)

Sutro Biopharma has reported Income towards Parent Company for 9 years, with the latest figure at -$46.8 million in Q4 2025.

• Quarterly Income towards Parent Company rose 35.46% year-over-year to -$46.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$182.7 million (up 19.66% YoY) and the FY2025 annual result came in at -$191.1 million, up 15.99% from the prior year.
• Income towards Parent Company climbed to -$46.8 million in Q4 2025 per STRO's latest filing, from -$56.9 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at $31.1 million in Q4 2023 and troughed at -$72.4 million in Q4 2024.
• A 5-year average of -$36.6 million and a median of -$38.8 million in 2022 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2023 and 2024: Income towards Parent Company jumped 189.78% in 2023, then tumbled 333.26% in 2024.
• Over 5 years, Income towards Parent Company stood at -$38.1 million in 2021, then climbed by 9.26% to -$34.6 million in 2022, then surged by 189.78% to $31.1 million in 2023, then plunged by 333.26% to -$72.4 million in 2024, then surged by 35.46% to -$46.8 million in 2025.
• According to Business Quant data, Income towards Parent Company over the past three periods registered -$46.8 million, -$56.9 million, and -$11.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.